ISSN 1016-5169 | E-ISSN 1308-4488
The Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Atrial Electromechanical Conduction Time [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2024; 52(4): 237-243 | DOI: 10.5543/tkda.2024.27546

The Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Atrial Electromechanical Conduction Time

Enes Çelik1, Murat Kerkütlüoğlu1, Murat Şahin2, Ekrem Aksu1, Akif Serhat Balcıoğlu1
1Department of Cardiology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Türkiye
2Department of Endocrinology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Türkiye


OBJECTIVE
This study aims to explore the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a newer class of oral antidiabetic drugs, on atrial electromechanical delay (EMD) in patients with type 2 diabetes mellitus (DM). This is particularly relevant given the significantly higher incidence of atrial fibrillation (AF) in diabetic patients compared to the general population. Atrial electromechanical delay is recognized as an important factor influencing the development of atrial fibrillation.


METHODS
This study included 30 type 2 DM patients (53.3% female, mean age 60.07 ± 10.03 years), initiating treatment with SGLT-2 inhibitors. The patients were assessed using echocardiography at baseline and again at 6 months, focusing on basic echocardiographic parameters and atrial electromechanical delay times (EMD) measured via tissue Doppler imaging.


RESULTS
No significant changes were observed in intra-atrial EMD times. However, significant reductions were noted in interatrial EMD times, decreasing from 15.13 ± 5.87 ms to 13.20 ± 6.12 ms (P = 0.029). Statistically significant shortening occurred in lateral pulmonary acceleration (PA) times (from 58.73 ± 6.41 ms to 54.37 ± 6.97 ms, P < 0.001), septal PA times (from 50.90 ± 6.02 ms to 48.23 ± 5), and tricuspid PA times (from 43.60 ± 6.28 ms to 41.30 ± 5.60 ms, P = 0.003). Additionally, there was a significant reduction in the E/e’ ratio from 8.13 ± 4.0 to 6.50 ± 2.37 (P = 0.003).


CONCLUSION
SGLT-2 inhibitors might positively influence atrial electromechanical conduction, reducing DM-related functional impairments and the risk of arrhythmias, particularly AF.

Keywords: Atrial electromechanical delay, atrial fibrillation, diabetes mellitus, SGLT-2 inhibitors

Corresponding Author: Enes Çelik, Türkiye
Manuscript Language: English
×
APA
NLM
AMA
MLA
Chicago
Copied!
CITE


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.